Driehaus Capital Management LLC Has $286,000 Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Driehaus Capital Management LLC significantly reduced its stake in Teva Pharmaceutical Industries by 99.4%, selling nearly 3 million shares and leaving them with just 18,631 shares valued at $286,000.
• Several other institutional investors entered or modified their positions in Teva during the first quarter, with a notable 403.4% increase in stake by Brooklyn Investment Group.
• Teva's stock has received multiple upgrades from various analysts, with the consensus rating now at "Buy" and an average price target of $24.71.

Driehaus Capital Management LLC cut its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 99.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,631 shares of the company's stock after selling 2,967,480 shares during the quarter. Driehaus Capital Management LLC's holdings in Teva Pharmaceutical Industries were worth $286,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. US Bancorp DE boosted its stake in Teva Pharmaceutical Industries by 6.5% in the first quarter. US Bancorp DE now owns 10,812 shares of the company's stock valued at $166,000 after buying an additional 656 shares in the last quarter. Bfsg LLC boosted its stake in Teva Pharmaceutical Industries by 7.8% in the first quarter. Bfsg LLC now owns 10,960 shares of the company's stock valued at $168,000 after buying an additional 790 shares in the last quarter. Factorial Partners LLC increased its holdings in shares of Teva Pharmaceutical Industries by 0.3% during the first quarter. Factorial Partners LLC now owns 333,000 shares of the company's stock worth $5,118,000 after buying an additional 1,000 shares in the last quarter. Yousif Capital Management LLC increased its holdings in shares of Teva Pharmaceutical Industries by 1.9% during the first quarter. Yousif Capital Management LLC now owns 55,986 shares of the company's stock worth $861,000 after buying an additional 1,033 shares in the last quarter. Finally, Mackenzie Financial Corp increased its holdings in shares of Teva Pharmaceutical Industries by 4.1% during the fourth quarter. Mackenzie Financial Corp now owns 29,889 shares of the company's stock worth $659,000 after buying an additional 1,171 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Down 1.3%

Shares of Teva Pharmaceutical Industries stock traded down $0.24 during midday trading on Thursday, reaching $18.53. The company had a trading volume of 7,372,759 shares, compared to its average volume of 12,047,567. The stock has a fifty day moving average price of $16.95 and a 200 day moving average price of $16.37. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The firm has a market cap of $21.25 billion, a PE ratio of -115.78, a P/E/G ratio of 1.09 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same period in the previous year, the firm earned $0.61 earnings per share. The firm's quarterly revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. Company insiders own 0.55% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on TEVA. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. UBS Group lowered their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Finally, Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $24.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.